Project Details
Description
DESCRIPTION: This application is from the FCCC. The 31-phosphorus (31-P)
nuclear magnetic resonance (NMR) spectroscopy (MRS) resonance of human
cancers in vivo reveals metabolic characteristics which differ from
those of normal tissues. These include elevations in PME, PDE, and of
cellular pH, and dimininution of PCr. Published studies show that MRS-
derived pH and MRI-derived T2 relaxation time predict response of soft
tissue sarcomas to radiation and hyperthermia, and that changes in PME's
predict response of several different human cancers to chemotherapy and
radiation. The applicant proposes a prospective trial to test the
hypotheses that in vivo 31-P MRS can predict sensitivity or resistance
to treatment inpatients with types of cancers especially well suited to
determine the clinical utility of MRS in cancer management, in
particular non-Hodgkin's lymphomas and locally-advanced primary breast
cancers.
This will be done by correlating response rate and disease-free survival
to metabolic features in the baseline spectrum and to changes in the
spectrum occurring early following initiation of treatment. This
application is the central one of 8 interactive R01 applications from
institutions cooperating to study over 1500 patients with non-Hodgkin's
lymphomas, locally-advanced breast cancers,sarcomas, and carcinomas of
the head and neck. Attention will be paid to patient selection, protocol
management, technical quality control and statistical analyses. The
state-of-the-art techniques used will be uniform across the 8
institutions and will include: (1) The use of dual-tuned
proton/phosphorus surface coils to interrogate various tumor anatomical
locations. (2) Proton-decoupling of phosphorus spectra to distinguish
individual components of phospholipid metabolites in the PME and PDE
regions. (3) Image-guided 3-dimensional chemical shift imaging to
accurately localize 13P NMR spectra to tumor masses, and (4) Molar
quantitation of metabolite concentrations in the tumors. This
application also proposes to establish standards for cooperative MRS
trials in other diseases and clinical settings, and seeks to pave the
way for clinical trials in which MRS could be used to intervene in the
selection of treatment regimens in individual patients with cancer.
Status | Finished |
---|---|
Effective start/end date | 5/18/95 → 8/31/04 |
Funding
- National Cancer Institute: US$1,178,001.00
ASJC Scopus Subject Areas
- Cancer Research
- Oncology
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.